NeuroPace (NPCE) EBIT Growth (3y) (2023 - 2026)
NeuroPace (NPCE) EBIT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.89 Bn | 173.59 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 127.82 Bn | 124.94 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 107.49 Bn | 98.27 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 67.24 Bn | 65.78 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 48.02 Bn | 44.34 Bn | 1.29 Bn | 7.13% |
| 6 | Dexcom | 28.25 Bn | 27.14 Bn | 750.30 Mn | 75.54% |
| 7 | GE HealthCare Technologies | 28.17 Bn | 25.89 Bn | 1.98 Bn | -2.70% |
| 8 | Smith & Nephew | 26.72 Bn | 26.14 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn | 34.83% |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | 12.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.53% |
| Dec 31, 2025 | 43.62% |
| Sep 30, 2025 | 36.59% |
| Jun 30, 2025 | 14.65% |
| Mar 31, 2025 | 19.21% |
| Dec 31, 2024 | 26.00% |
| Sep 30, 2024 | 12.08% |
| Jun 30, 2024 | -10.60% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -19.22% |
| Sep 30, 2023 | -72.16% |
| Jun 30, 2023 | -31.60% |
| Mar 31, 2023 | -15.08% |